Venous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry

Simple item page
dc.contributor.authorBikdeli, Behnood
dc.contributor.authorJiménez, David
dc.contributor.authorDemelo Rodríguez, Pablo
dc.contributor.authorGaleano Valle, Francisco
dc.contributor.authorPorras, José Antonio
dc.contributor.authorBarba, Raquel
dc.contributor.authorAy, Cihan
dc.contributor.authorMalý, Radovan
dc.contributor.authorBraester, Andrei
dc.contributor.authorImbalzano, Egidio
dc.contributor.authorRosa, Vladimir
dc.contributor.authorLecumberri, Ramón
dc.contributor.authorSiniscalchi, Carmine
dc.contributor.authorFidalgo, Ángeles
dc.contributor.authorOrtiz, Salvador
dc.contributor.authorMonreal, Manuel
dc.date.accessioned2023-06-22T10:50:17Z
dc.date.available2023-06-22T10:50:17Z
dc.date.issued2022-01-18
dc.description.abstractBackground: Venous thromboembolism (VTE)—including deep vein thrombosis, pulmonary embolism, and cerebral venous sinus thrombosis (CVST)—may occur early after vaccination against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We sought to describe the site, clinical characteristics, and outcomes of VTE after vaccination against SARS-CoV-2. Methods: In a prospective study using the Registro Informatizado de Enfermedad TromboEmbólica (RIETE) platform, patients with VTE 4–30 days after vaccination against SARS-CoV-2 (1 February 2021 through 30 April 2021) were included. VTE patients recruited from the same centers into RIETE in the same months in 2018–2019 were selected as the reference group. All-cause mortality and major bleeding were the main study outcomes. Results: As of 30 April 2020, 102 patients with post-vaccination VTEs had been identified (28 after adenovirus-based vaccination [ChAdOx1 nCov-19; AstraZeneca] and 74 after mRNA-based vaccination [mRNA-1273; Moderna, and BNT162b2; Pfizer]). Compared with 911 historical controls, patients with VTE after adenovirus-based vaccination more frequently had CVST (10.7% vs. 0.4%, p < 0.001) or thrombosis at multiple sites (17.9% vs. 1.3%, p < 0.001), more frequently had thrombocytopenia (40.7% vs. 14.7%, p < 0.001), and had higher 14-day mortality (14.3% vs. 0.7%; odds ratio [OR]: 25.1; 95% confidence interval [CI]: 6.7–94.9) and major bleeding rates (10.3% vs. 1.0%, OR: 12.03, 95% CI: 3.07–47.13). The site of thrombosis, accompanying thrombocytopenia, and 14-day mortality rates were not significantly different for patients with VTE after mRNA-based vaccination, compared with historical controls. Conclusions: Compared with historical controls, VTE after adenovirus-based vaccination against SARS-CoV-2 is accompanied by thrombocytopenia, occurs in unusual sites, and is associated with worse clinical outcomes.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.refereedTRUE
dc.description.statuspub
dc.eprint.idhttps://eprints.ucm.es/id/eprint/73385
dc.identifier.doi10.3390/v14020178
dc.identifier.issn1999-4915
dc.identifier.officialurlhttps://doi.org/10.3390/v14020178
dc.identifier.relatedurlhttps://www.mdpi.com/1999-4915/14/2/178/htm
dc.identifier.urihttps://hdl.handle.net/20.500.14352/71757
dc.issue.number2
dc.journal.titleViruses
dc.language.isoeng
dc.page.initial178
dc.publisherMDPI
dc.rightsAtribución 3.0 España
dc.rights.accessRightsopen access
dc.rights.urihttps://creativecommons.org/licenses/by/3.0/es/
dc.subject.keywordvenous thromboembolism
dc.subject.keywordCOVID-19
dc.subject.keywordSARS-CoV-2
dc.subject.keywordvaccination
dc.subject.ucmInmunología
dc.subject.unesco2412 Inmunología
dc.titleVenous Thrombosis within 30 Days after Vaccination against SARS-CoV-2 in a Multinational Venous Thromboembolism Registry
dc.typejournal article
dc.volume.number14
dspace.entity.typePublication
relation.isAuthorOfPublication64523ef8-6ac2-473f-8f1a-ad098fc02e8a
relation.isAuthorOfPublicatione065c10e-a257-454b-a5e6-92d6c1107129
relation.isAuthorOfPublication.latestForDiscovery64523ef8-6ac2-473f-8f1a-ad098fc02e8a
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
viruses-14-00178-v2.pdf
Size:
3.49 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos